MABVAX THERAPEUTICS HOLDINGS, INC. (MBVX) Files An 8-K Regulation FD Disclosure

On November 14, 2016, MabVax Therapeutics Holdings, Inc. (the
Company) issued a press release that reported on interim safety
and imaging results from two phase I clinical trials in the
Companys HuMab-5B1 antibody development program. The press
release is attached hereto as Exhibit 99.1.

The Company also announced that it would hold a conference call
to discuss both the third quarter financial results and interim
safety and imaging results from the two phase I clinical results
at the following date and time:

When: November 14, 2016, 4:15 p.m. EST

Dial-in: (877) 407-8293 or (201) 689-8349

Conference ID: MabVax Therapeutics Third Quarter 2016 Conference
Call

A replay of the conference call will be available for 2 weeks
shortly after the call. To access the replay, please dial
877-660-6853 or 201-612-7415. Conference ID: 13649739.

The information in this report, including Exhibit 99.1 hereto, is
being furnished and shall not be deemed filed for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended,
nor shall it be incorporated by reference into any registration
statement or other document to the Securities Act of 1933, as
amended, except as expressly set forth in such filing.

ITEM 9.01

FINANCIAL STATEMENTS AND EXHIBITS

(d)Exhibits.

The exhibit listed in the following Exhibit Index is furnished
with this Current Report on Form 8-K.

Exhibit No.		Description
99.1		Press release issued November 14, 2016